pharma · Major Depressive Disorder · Migraine · AXSM
Axsome Therapeutics
Axsome Therapeutics trial registry — 36 ClinicalTrials.gov studies with program phase, status, and indication context.
One World Trade Center, New York, NY 10007, US HQ
2012 Founded
981 Employees
Public company Type
AXSM · NYSE Ticker
Company details
- Status
- Public
- HQ
- One World Trade Center, New York, NY 10007, US
- Founded
- 2012
- Employees
- 981
- Programs
- 28
- Drugs
- 12
- Patents
- 162
Axsome Therapeutics clinical trials
Registry index of 36 ClinicalTrials.gov studies linked to Axsome Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Axsome Therapeutics trial registry — 36 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Axsome Therapeutics.
-
SOL-BED-303 — Phase 3
Clinical update -
Solriamfetol Oral Tablet — Approved
Clinical update -
Solriamfetol 150 mg Oral Tablet — Phase 1
Clinical update -
AXS-07 (MoSEIC meloxicam and rizatriptan) — Phase 3
Clinical update -
AXS-07 (meloxicam-rizatriptan) — Phase 3
Clinical update -
AXS-07 — Phase 3
Clinical update -
Dextromethorphan-Bupropion — Phase 2
Clinical update -
AXS-14 (Esreboxetine) — Phase 3
Clinical update
Trial registry
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT04947553CT.gov ↗
AXS-05 (dextromethorphan-bupropion)
Agitation in Patients With Dementia of the Alzheimer's Type
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT06736509CT.gov ↗
AXS-05 (dextromethorphan-bupropion)
Agitation in Patients With Dementia of the Alzheimer's Type
-
CT.gov ↗ -
CT.gov ↗ - NCT07484217CT.gov ↗
Solriamfetol 150 MG
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
-
CT.gov ↗